Evidence map›Paper›PMID 40640386›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Repeat biopsies in membranous lupus nephritis in the era of target antigen identification.

Elodie Bernhard, Hamza Sakhi, Julie Oniszczuk, Constance Guillaud, Nicolas Limal, Ines Allioua, Narindra Jouan, Stephanie Guillet, Carine Diet, Bertrand Godeau and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elodie BernhardUniv Paris Est Créteil, 94010, Créteil, France.
Hamza SakhiUniv Paris Est Créteil, 94010, Créteil, France.
Julie OniszczukNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Constance GuillaudInternal Medicine Department, AP-HP, Hôpitaux Universitaires Henri Mondor, Centre National de Référence Des Cytopénies Auto-Immunes de L'Adulte, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », 94010, Créteil, France.
Nicolas LimalInternal Medicine Department, AP-HP, Hôpitaux Universitaires Henri Mondor, Centre National de Référence Des Cytopénies Auto-Immunes de L'Adulte, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », 94010, Créteil, France.
Ines AlliouaNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Narindra JouanNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Stephanie GuilletInternal Medicine Department, AP-HP, Hôpitaux Universitaires Henri Mondor, Centre National de Référence Des Cytopénies Auto-Immunes de L'Adulte, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », 94010, Créteil, France.
Carine DietNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Bertrand GodeauUniv Paris Est Créteil, 94010, Créteil, France.
Philippe RemyNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Vincent AudardUniv Paris Est Créteil, 94010, Créteil, France.
Nizar JoherNephrology and Renal Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », 94010, Créteil, France.
Anissa MoktefiUniv Paris Est Créteil, 94010, Créteil, France. anissa.moktefi@aphp.fr.ORCID http://orcid.org/0000-0002-6015-3979

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In membranous lupus nephritis (LN), positivity for the target antigen exostosin 1/2 (EXT) is associated with a lower chronicity index (CI) at first biopsy and a lower risk of progression to end-stage kidney disease (ESKD) compared to EXT-negative patients. Repeat kidney biopsies (RKB) in LN may reveal increasing CI and class transition with prognostic significance. In a cohort of membranous LN with RKB, we assessed the variation in EXT and neural cell adhesion molecule 1 (NCAM1) expression and their association with class III/IV + V transition and renal outcomes. Thirty patients with 78 biopsies were enrolled. Index biopsies included 60% EXT-NCAM1-, 34% EXT + NCAM1-, 3% EXT-NCAM1 + and 3% EXT + NCAM1 + cases. Target antigen switch occurred in 3 (10%) cases (2 EXT + to EXT-; 1 NCAM1- to NCAM1 +) with favorable renal outcomes. EXT-positive and EXT-negative groups had similar clinico-pathological characteristics at baseline and at the end of follow-up, with comparable numbers of RKB, median CI increase, class transition rates, and renal outcomes. After a median follow-up of 8.8 years, 9 (32%) patients developed ESKD or glomerular filtration rate decrease > 40%. These patients exhibited higher median first biopsy CI (p = 0.04) and higher median serum creatinine level (p = 0.01), higher median CI (p = 0.02), and higher thrombotic microangiopathy (TMA) rate (p = 0.03) at second biopsy. TMA on any follow-up biopsy was more frequent in the adverse outcome group (p = 0.001). Not only EXT but also NCAM1 expression may vary in RKB during membranous LN. EXT-positive and EXT-negative patients had similar presentation and course, while TMA and CI compromised renal outcomes.

Indexed as

Glomerulonephritis, MembranousKidneyLupus NephritisAdultBiomarkersBiopsyCD56 AntigenDisease ProgressionExostosin 1Exostosin 2FemaleHumansKidney Failure, ChronicMaleMiddle AgedPrognosisBiomarkersCD56 AntigenExostosin 1Exostosin 2NCAM1 protein, humanExostosinLupus nephritisMembranous nephropathyNCAM1Repeat kidney biopsiesTarget antigen

Identifiers

PMID40640386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.